[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370454-105":59,"doc-detail-370454-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cdc25a-inhibition-sensitizes-melanoma-cells-to-doxorubicin-and-nk-cell-therapy","CDC25A inhibition sensitizes melanoma cells to doxorubicin and NK cell therapy","","Cell division cycle 25 (CDC25) phosphatases regulate cell-cycle transitions and checkpoint responses during DNA damage. While the CDC25 family shows oncogenic activity across cancers, its expression patterns and functional roles in multiple tumor types remain insufficiently mapped. Using pan-cancer analyses and melanoma-focused investigation, the study links CDC25 dysregulation with worse outcomes, identifies regulation by DNA methylation and genetic alterations, and demonstrates that CDC25A inhibition reduces melanoma proliferation and enhances sensitivity to chemotherapy and NK cell therapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cdc25a-inhibition-sensitizes-melanoma-cells-to-doxorubicin-and-nk-cell-therapy/370454/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cdc25a-inhibition-sensitizes-melanoma-cells-to-doxorubicin-and-nk-cell-therapy/370454.png","ImageObject",300,407,{"name":92,"@type":93},"Mia  ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the biological role of CDC25 phosphatases in cancer?","Question",{"text":112,"@type":113},"CDC25 phosphatases regulate cell-cycle phase transitions and checkpoint machinery in response to DNA damage. Abnormal CDC25 family expression contributes to cancer initiation, progression, and poor prognosis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What did the study find about CDC25 family expression across cancers?",{"text":117,"@type":113},"CDC25 family members show significantly abnormal expression in most cancers and correlate with poorer prognosis. Their regulation also differs across cancers via DNA methylation and genetic alterations.",{"name":119,"@type":110,"acceptedAnswer":120},"How does CDC25A inhibition affect melanoma treatment response?",{"text":121,"@type":113},"CDC25A inhibition suppresses melanoma cell proliferation and sensitizes melanoma cells to chemotherapy (doxorubicin) and NK cell therapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},370454,1790641200,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},687207024478,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nCDC25A inhibition sensitizes melanoma cells to doxorubicinand NK cell therapy  \nXinyue Gao 1,6, Feichang Liu1,2,6, Bo Zhang1,3,6, Tianyi Ren4,6, You Zheng 1, Zubiao Niu1, He Ren 1,3, Chenyu Liu1,3, Chengzuo Jiang 1,5, Chenxi Wang 1 ✉, Hongyan Huang 3 ✉, Li Ma 2 ✉ and Qiang Sun 1 ✉  \n© The Author(s) 2025  \n\n|  | Cell division cycle 25 (CDC25) phosphatases serve as crucial regulators of cell cycle phase transitions and essential components of the checkpoint machinery involved in DNA damage response. Emerging evidence indicates the oncogenic potential of CDC25 family members across various cancers. However, comprehensive insights into the expression pattern and function of the CDC25 family in diverse cancers remain unexplored. In our study, we investigated CDC25 family using multiple databases, including gene expression levels, molecular signatures, diagnosis value, and prognostic value in pan-cancer. Furthermore, we focused on melanoma and systematically explored CDC25A expression and its clinical correlations. As a result, the expression of CDC25 family members is significantly abnormal in most cancers, correlating with poorer prognosis. CDC25 family members are differently regulated by DNA methylation and genetic alterations across various cancers. In addition, CDC25 family plays a critical role in the malignant progression of melanoma. Functional investigation reveals that CDC25A inhibition suppresses the proliferation of melanoma cells and sensitizes melanoma cells to chemotherapy and NK cell therapy. In conclusion, our study suggests that CDC25 family may serve as a significant biomarker for diagnosis and prognosis across multiple cancers, with CDC25A as a promising |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| therapeutic target for melanoma. |  |  |\n|  | Cell Death and Disease (2025)16:276; [https://doi.org/10.1038/s41419-025-07598-w](https://doi.org/10.1038/s41419-025-07598-w) |  |\n|  |  |  |\n\nINTRODUCTION  \nCancer is one of the leading causes of death worldwide, posing asignificant barrier to the improvement of public health [1] . The latest global cancer statistics, published in 2024, report nearly 20 million new cancer cases and 10 million cancer-related deaths in 2022 [2] . Although chemotherapy, targeted therapy and immunotherapy have shown remarkable advancements in recent decades, substantial challenges persist in cancer treatment, including tumor resistance, poor clinical responses, and the absence of reliable biomarkers [3, 4] . The molecular complexity of melanoma, from driver mutations to dynamic phenotype switching, makes it a model for understanding cancer evolution and therapy resistance [5, 6] . Over the past decades, novel therapeutic strategies including immunotherapy, targeted therapy, and combination therapy are emerging, which have led to great improvements in the survival of advanced patients [7, 8] . The absence of early diagnostic biomarkers and therapeutic limitations such as off-target effects remain major clinical challenges in the contemporary treatment of melanoma. Therefore, identifying novel biomarkers that can accurately predict treatment efficacy has become crucial.  \nAberrant cell cycle progression is a key mechanism in tumorigenesis [9] . In tumors, it typically drives continuous and  \nexcessive cell division, thereby promoting tumor progression [10] . Consequently, key regulators of the cell cycle may serve as efficient targets for anti-tumor therapies. Cell division cycle 25 (CDC25) dual phosphatases are essential components of cell cycle control which activate cyclin-dependent kinases (CDKs) through dephosphorylation, thereby promoting cell cycle progression. The abnormal expression and distribution of CDC25 family members are implicated in cancer initiation, progression, and poor prognosis. In mammalian cells, the CDC25 phosphatase famil","cbCaihd5aaBj8vle","https://ap.wps.com/l/cbCaihd5aaBj8vle","pdf",8284895,15,"English","# Introduction\n## Background on cancer burden and melanoma challenges\n## Cell cycle dysregulation and CDC25 function\n## CDC25A roles and clinical relevance","[{\"question\":\"What is the biological role of CDC25 phosphatases in cancer?\",\"answer\":\"CDC25 phosphatases regulate cell-cycle phase transitions and checkpoint machinery in response to DNA damage. Abnormal CDC25 family expression contributes to cancer initiation, progression, and poor prognosis.\"},{\"question\":\"What did the study find about CDC25 family expression across cancers?\",\"answer\":\"CDC25 family members show significantly abnormal expression in most cancers and correlate with poorer prognosis. Their regulation also differs across cancers via DNA methylation and genetic alterations.\"},{\"question\":\"How does CDC25A inhibition affect melanoma treatment response?\",\"answer\":\"CDC25A inhibition suppresses melanoma cell proliferation and sensitizes melanoma cells to chemotherapy (doxorubicin) and NK cell therapy.\"}]","CDC25A inhibition sensitizes melanoma cells to doxorubicin and NK cell therapy | PDF",1790188619,38]